[1] Bartram J, Wade R, Vora A, et al. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up:results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003[J]. Arch Dis Child, 2016, 101(5):449-454.
[2] Athale UH, Gibson PJ, Bradley NM, et al. Minimal residual disease and childhood leukemia:standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group[J]. Pediatr Blood Cancer, 2016, 63(6):973-982.
[3] Campana D. Progress of minimal residual disease studies in childhood acute leukemia[J]. Curr Hematol Malig Rep, 2010, 5(3):169-176.
[4] 徐瑞琴, 陆小云, 张敏. 急性白血病缓解期微小残留病灶与预后的关系[J]. 临床血液学杂志, 2016, 29(3):209-212.
[5] Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Leukemia, 2013, 27(3):635-641.
[6] Karawajew L, Dworzak M, Ratei R, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia[J]. Haematologica, 2015, 100(7):935-944.
[7] Cheng SH, Lau KM, Li CK, et al. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction[J]. PLoS One, 2013, 8(7):e69467.
[8] 卢新天. 儿童急性白血病预后影响因素[J]. 实用儿科临床杂志, 2011, 26(15):1155-1158.
[9] Rocha JM, Xavier SG, de Lima Souza ME, et al. Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.[J]. Mediterr J Hematol Infect Dis, 2016, 8(1):e2016024.
[10] Gandemer V, Pochon C, Oger E, et al. Clinical value of pretransplant minimal residual disease in childhood lymphoblastic leukaemia:the results of the French minimal residual diseaseguided protocol[J]. Br J Haematol, 2014, 165(3):392-401.
[11] Campana D. Minimal residual disease[J]. Leukemia Supplements, 2012(1):S3-S4.
[12] Campana D, Coustan-Smith E. Measurements of treatment response in childhood acute leukemia[J]. Korean J Hematol, 2012, 47(4):245-254.
[13] Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials:Proceedings of the Second International Symposium on MRD Assessment in Kiel, Germany, 18-20 September 2008[J]. Leukemia, 2010, 24(3):521-535.
[14] Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML[J]. Bone Marrow Transplant, 2014, 49(5):679-683.
[15] Martelli MP, Sportoletti P, Tiacci E, et al. Mutational landscape of AML with normal cytogenetics:Biological and clinical implications[J]. Blood Rev, 2013, 27(1):13-22.
[16] Baraka A, Sherief LM, Kamal NM, et al. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flow cytometry[J]. Int J Hematol, 2017, 105(6):784-791.
[17] 常英军, 赵晓甦. 多参数流式细胞仪检测急性髓细胞白血病微小残留病:挑战与对策[J]. 临床荟萃, 2016, 31(6):581-584.
[18] Getta BM, Devlin SM, Levine RL, et al. Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(7):1064-1071.
[19] Balduzzi A. Minimal residual disease assessment by nextgeneration sequencing. Better tools to gaze into the crystal ball?[J]. Bone Marrow Transplant, 2017, 52(7):952-954.
[20] 郭青, 金润铭. 微小残留病检测指导白血病治疗的研究进展[J]. 中国实用儿科杂志, 2016, 31(4):264-268.
[21] Coustan-Smith E, Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia:a comparative approach to molecular testing[J]. Best Pract Res Clin Haematol, 2010, 23(3):347-358.
[22] Coustan-Smith E, Sancho J, Hancock ML. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia[J]. Blood, 2002, 100(7):2399-2402.
[23] 徐翀, 何妙侠, 郑建明. 儿童急性淋巴细胞白血病微小残留病检测及其进展[J]. 检验医学, 2013, 28(4):342-347.
[24] Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients[J]. Cancer Med, 2016, 5(2):265-274.
[25] Wang L, Gao L, Xu S, et al. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML)[J]. Ann Hematol, 2014, 93(10):1685-1694.
[26] Kotrova M, van der Velden VHJ, van Dongen JJM, et al. Nextgeneration sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL[J]. Bone Marrow Transplant, 2017, 52(7):962-968.
[27] Sekiya Y, Xu Y, Muramatsu H, et al. Clinical utility of nextgeneration sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia[J]. Br J Haematol, 2017, 176(2):248-257.
[28] Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH[J]. Clin Cancer Res, 2014, 20(17):4540-4548.
[29] Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL:results of the AIEOP-BFM-ALL 2000 study[J]. Blood, 2011, 118(8):2077-2084.
[30] Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia[J]. Br J Haematol, 2013, 162(5):606-620.
[31] Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003):a randomised controlled trial[J]. Lancet Oncol, 2013, 14(3):199-209.
[32] Pui C, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia:a prospective study[J]. Lancet Oncol, 2015, 16(4):465-474.
[33] Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia:prognostic relevance of early and late assessment[J]. Leukemia, 2015, 29(8):1648-1655.
[34] Salah-Eldin M, Abousamra NK, Azzam H. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia:results of prospective study[J]. Med Oncol, 2014, 31(5):938.
[35] Karol SE, Coustan-Smith E, Cao X, et al. Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy[J]. Br J Haematol, 2015, 168(1):94-101.
[36] Umeda K, Iwai A, Kawaguchi K, et al. Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia[J]. Pediatr Transplant, 2017, 21(4):e12926.
[37] 冯建华, 汤永民, 徐晓军. 流式细胞仪检测儿童急性髓系白血病微小残留病的研究进展[J]. 中华儿科杂志, 2013, 51(3):231-234.
[38] Balduzzi A, Di Maio L, Silvestri D, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia:is there any room for intervention?[J]. Br J Haematol, 2014, 164(3):396-408.
[39] Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with veryhigh-risk leukemia[J]. Blood, 2012, 120:468-472.
[40] Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL[J]. Bone Marrow Transplant, 2008, 42(3):187-196.
[41] Bernal T, Diez-Campelo M, Godoy V, et al. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Leuk Res, 2014, 38(5):551-556.